With 45-plus locations and more than 225 providers, the physician-owned practice makes it simpler for families to get all the appointments they need, while ensuring comprehensive, complete care.

Presentations highlighting CRISPR genetic and epigenetic editing therapies, machine learning, and corporate updates at multiple industry-leading events in Fall 2025ALAMEDA, Calif.--(BUSINESS ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointment ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that management will ...

Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced participation in ...

Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented ...

Camzyos (mavacamten) presentations include real-world outcomes from COLLIGO-HCM and a pooled monotherapy analysis from four Phase 3 studiesResults add to growing body of evidence supporting the ...

OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 ...

Black Book Research survey reveals compliance gaps, weak technology readiness, and mounting patient care risks as Medicare ...

POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug ...

Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 millionIMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell ...

Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing ...